Orphazyme: Bull story below Bear price
Research Update
2020-12-17
07:25
Redeye revisits the Orphazyme case in light of exceptional news flow in the first half of 2021. We reiterate our positive fundamental view while raising fair value. Although the stock is now trading below our Bear Case, we see no intrinsic reason for its underperformance and expect the attractive pipeline-in-a-product – which holds blockbuster potential – to lift it.
Anders Hedlund
Disclosures and disclaimers